Ireland's Glanbia, a global nutrition company known for brands like Optimum Nutrition, has raised its full-year profit forecast after a surge in demand for its protein powders and ready-to-drink shakes. The company attributes part of that strength to people using GLP-1 weight-loss drugs, who often turn to protein supplements to maintain muscle mass while losing weight.
Glanbia now expects adjusted earnings per share (EPS) to grow by 17% to 20% this year at constant currencies, a significant upgrade from its late-April guidance, which had called for growth at the top of a 7% to 11% range. The revised outlook follows a strong first half, during which adjusted EPS climbed 30%.
What's driving the demand?
The biggest driver is Optimum Nutrition, Glanbia's flagship sports nutrition brand. First-half sales for the brand rose sharply, fueled by increased consumption of protein powders and shakes. The company says the trend is partly linked to the growing use of GLP-1 medications, which are prescribed for diabetes and weight loss. As more people take these drugs, they often need to preserve lean muscle, and protein supplements have become a go-to solution.
This is a notable shift for a company that has traditionally catered to athletes and fitness enthusiasts. The broader wellness trend, combined with the rise of weight-loss drugs, has opened a new customer base for protein products.
Cost pressures and price hikes
Despite the demand boost, Glanbia faces rising costs. Whey, a key ingredient in protein powders, has become more expensive. The company says it expects to implement further price increases to offset these higher input costs. That could mean consumers will pay more for their favorite protein shakes in the coming months.
For investors, the key question is whether demand will remain strong enough to absorb those price hikes. Glanbia's management appears confident, citing the resilience of its brands and the ongoing shift toward health and wellness.
What it means for investors
Glanbia's upgraded guidance is a positive signal for shareholders, but it also highlights the delicate balance between growth and cost inflation. The company's ability to pass on higher costs without denting demand will be crucial in the second half of the year.
For everyday investors, this news underscores the growing intersection between pharmaceuticals and nutrition. As GLP-1 drugs become more widespread, companies that supply complementary products—like protein supplements—could see sustained tailwinds. However, it's worth noting that this is a competitive space, and consumer preferences can shift quickly.
Glanbia's performance also reflects broader trends in the consumer staples sector, where companies are navigating input cost inflation while trying to maintain margins. The company's focus on premium brands and its exposure to the health and wellness trend may help it weather these pressures better than some peers.
Investors will be watching Glanbia's next earnings report for signs that the momentum is continuing, as well as any updates on pricing strategy and cost management. The company's ability to execute on its growth plans while managing costs will be key to sustaining its upgraded outlook.
In the meantime, the news is a reminder that even in a challenging economic environment, companies that tap into structural trends—like the rise of GLP-1 drugs—can find new avenues for growth.
